86 related articles for article (PubMed ID: 32484665)
1. Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer.
Peddi S; Roberts SK; MacKay JA
Biomacromolecules; 2020 Mar; 21(3):1091-1102. PubMed ID: 31927993
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Aspects and Molecular Targets of Autophagy to Control Pancreatic Cancer Management.
Rahman MA; Ahmed KR; Rahman MDH; Parvez MAK; Lee IS; Kim B
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740481
[TBL] [Abstract][Full Text] [Related]
3. Berunda Polypeptides Carrying Rapalogues Inhibit Tumor mTORC1 Better than Oral Everolimus.
Peddi S; MacKay JA
Biomacromolecules; 2020 Aug; 21(8):3038-3046. PubMed ID: 32484665
[TBL] [Abstract][Full Text] [Related]
4. Berunda Polypeptides: Multi-Headed Fusion Proteins Promote Subcutaneous Administration of Rapamycin to Breast Cancer
Dhandhukia JP; Li Z; Peddi S; Kakan S; Mehta A; Tyrpak D; Despanie J; MacKay JA
Theranostics; 2017; 7(16):3856-3872. PubMed ID: 29109782
[TBL] [Abstract][Full Text] [Related]
5. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.
Shi P; Aluri S; Lin YA; Shah M; Edman M; Dhandhukia J; Cui H; MacKay JA
J Control Release; 2013 Nov; 171(3):330-8. PubMed ID: 23714121
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular effects of the mTOR inhibitor everolimus.
Saran U; Foti M; Dufour JF
Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
[TBL] [Abstract][Full Text] [Related]
7. The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review.
Lin H; Salech F; Lim A; Vogrin S; Duque G
Aging Clin Exp Res; 2022 Oct; 34(10):2317-2333. PubMed ID: 35861940
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors.
Zhang Y; Yan H; Xu Z; Yang B; Luo P; He Q
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):767-774. PubMed ID: 31478386
[No Abstract] [Full Text] [Related]
9. Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease.
Lee C; Guo H; Klinngam W; Janga SR; Yarber F; Peddi S; Edman MC; Tiwari N; Liu S; Louie SG; Hamm-Alvarez SF; MacKay JA
Mol Pharm; 2019 Jul; 16(7):3024-3039. PubMed ID: 31095909
[TBL] [Abstract][Full Text] [Related]
10. FKBP Ligands-Where We Are and Where to Go?
Kolos JM; Voll AM; Bauder M; Hausch F
Front Pharmacol; 2018; 9():1425. PubMed ID: 30568592
[TBL] [Abstract][Full Text] [Related]
11. Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis.
Peddi S; Pan X; MacKay JA
Front Pharmacol; 2018; 9():1184. PubMed ID: 30386244
[TBL] [Abstract][Full Text] [Related]
12. Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.
Turner MR; Balu-Iyer SV
J Pharm Sci; 2018 May; 107(5):1247-1260. PubMed ID: 29336981
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
